- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01098422
A Study of Yttrium-90 Radioactive Resin Microspheres to Treat Colorectal Adenocarcinoma Metastatic to the Liver
A Phase II Study of Yttrium-90 Radioactive Resin Microspheres in the Treatment of Colorectal Adenocarcinoma Metastatic to the Liver After Failure of First-Line Combination Chemotherapy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a phase II, single-arm study of Yttrium-90 (Y-90) radioactive resin microspheres in the treatment of colorectal adenocarcinoma metastatic to the liver in patients who have had progressive disease through first line combination chemotherapy or have otherwise failed first line chemotherapy due to toxicity. Expected enrollment at University of California, San Diego (UCSD) is approximately 34 subjects.
The dose of Yttrium-90 radioactive resin microspheres is calculated based on body surface area (to estimate normal liver volume), percentage of total liver represented by the targeted lobe, and percentage of the lobe that is occupied by tumor, corrected for percentage lung shunt. The prescribed dose, calculated by the nuclear medicine physician, will be delivered by the interventional radiologist using the standard delivery system with frequent fluoroscopic monitoring to assure ante grade blood flow immediately after treatment. Additional current standard practice includes obtaining a nuclear medicine scan of the patient immediately after each therapeutic Yttrium-90 microspheres administration to prove delivery of the agent to the targeted portion of the liver and absence of either extra-hepatic Yttrium-90 delivery or free Yttrium-90.
Blood samples will be obtained one week after the first treatment with microspheres. If the patient has bi-lobar disease and the results of lab tests meet protocol specified criteria, the dose will be repeated in the initially-untreated lobe. If the lab tests do not meet protocol specified criteria (i.e. study inclusion/exclusion criteria), the treatment will be deferred for fourteen days and labs repeated. If they are then within parameters, the patient will receive the second dose. If they are not within parameters, the patient will proceed to chemotherapy.
Patients will remain off chemotherapy after their final microspheres treatment for a minimum of three weeks. Second line treatment options include FDA approved anti-neoplastic agents used in colorectal cancer metastatic to the liver with the exception of bevacizumab and capecitabine, which has been less rigorously studied with relation to Yttrium-90 radioactive microspheres and therefore will not be used. When patients are found to have progressive disease while receiving second line chemotherapy, they will then undergo a comprehensive clinical, laboratory, and imaging assessment and enter the follow-up phase in which they are assessed every five to seven months until death or withdrawal of consent.
A contrast enhanced ultrasound (CEUS) will be performed pre microsphere treatment (within 14 days), post microsphere treatment (2 weeks, 4 weeks, 8 weeks and 12 weeks post the microsphere treatment). If patients require two treatments with microspheres, they will be evaluated 2, 4, 8 and 12 weeks post the second treatment.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
La Jolla, California, United States, 92093
- The Rebecca and John Moores UCSD Cancer Center
-
San Diego, California, United States, 92103
- UCSD Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically confirmed colorectal carcinoma. Liver metastasis will be confirmed by either PET scan or biopsy.
- Ability to understand and willingness to sign written informed consent
- Minimum of 18 years of age
- Liver dominant metastases measurable by CT or MRI and therefore amenable to serial assessment using RECIST criteria
- Progressive disease of metastatic colorectal carcinoma on first line combination chemotherapy with a 5-fluorouracil/leucovorin with oxaliplatin (FOLFOX) based regimen (Folinic Acid, Oxaliplatin and Fluorouracil)or failure of first line chemotherapy due to toxicity
- Candidate for second line chemotherapy with a fluorouracil, leucovorin, and irinotecan (FOLFIRI) regimen. Per standard of care, second line chemotherapy will not include Bevacizumab.
- Karnofsky Performance Score (KPS) of 70% or greater
- Life expectancy of greater than or equal to four months by investigator estimation
- Females with negative urine or serum pregnancy test
- Effective double barrier contraception for a minimum of two months following the final infusion of microspheres
- Patients who are not candidates for transarterial chemoembolization (TACE), thermal ablation or surgical resection
Exclusion Criteria:
- Dominant extra-hepatic disease including cerebral metastases or other extra-hepatic metastases that are symptomatic
- Large volume ascites assessed by cross sectional CT imaging
- Any chemotherapy < 4 weeks prior to the first microsphere treatment
- Anticipated to need Avastin chemotherapy within eight weeks of day M1
- Absolute neutrophil count (ANC) < 1.5 x 109/L
- Platelets (PLT) < 60,000/mm3
- Hemoglobin (Hgb) < 9.0 gm/dL
- Prothrombin time (PT) or Partial Prothrombin time (PTT) > upper limit of normal (ULN)
- Serum Creatinine > 2.0 mg/dL
- Forced expiratory volume (FEV1) < 1L by baseline pulmonary function tests (ordered if investigator judges it to be clinically indicated)
- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 5 times upper limits of normal (ULN) or total bilirubin > 2.0 mg/dL
- History of incompetent sphincter of oddi (e.g.: sphincterotomy, biliary-enteric anastamosis, or percutaneous biliary drain)
- Severe hypoalbuminemia (albumin < 2.0 g/dL)
- Alkaline phosphatase > 2.5 times ULN
- Greater than 20% lung shunting (determined by the MAA - Tc 99 nuclear medicine lung shunt scan)
- Pre assessment angiogram and MAA scan demonstrating any uncorrectable activity in the stomach, bowel or pancreas
- Major surgery < 4 weeks prior to the first microsphere treatment
- Female who is pregnant or nursing
- Men and women of childbearing potential wishing to conceive < 2 months following the completion of the microsphere portion of the study.
- Any investigational agent administered < 4 weeks prior to microsphere treatment
- A known history of hepatitis B or hepatitis C
- Known hypersensitivity to any component of microsphere infusion
- History of, or current coagulation or bleeding disorder
- History of significant hepatic cirrhosis, fibrosis or hemochromatosis
- History of malignancy, other than colorectal cancer, within five years of the start of study participation, except in situ cervical or skin cancer
- Active severe infection or any other concurrent disease or medical conditions that are likely to interfere with the study as judged by the investigator
- Prior treatment with radioactive microspheres or external beam radiation therapy to the liver
- Prophylactic anticoagulation and nonsteroidal antiplatelet drugs are only a contraindication, if the PT/PTT are above the ULN. Plavix (clopidogrel) will need to be stopped 5 days prior to the hepatic-angiogram and the microsphere procedures, then started the next day.
- History of right to left, bi-directional or transient right to left cardiac shunts, worsening or clinically unstable congestive heart failure, acute myocardial infarction or acute coronary syndromes serious ventricular arrhythmias or high risk for arrhythmias due to prolongation of the QT interval, respiratory failure as manifested by signs or symptoms of carbon dioxide retention or hypoxemia or severe emphysema, pulmonary emboli or other conditions that causes pulmonary hypertension due to compromised pulmonary arterial vasculature
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Yttrium-90 Radioactive Resin Microspheres
|
An injectable formulation of the radioisotope yttrium-90 encapsulated in resin microspheres with potential antineoplastic activity.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PFS
Time Frame: 2 years
|
Progression-free survival assessed by Response Evaluation Criteria in Solid Tumors (RECIST) criteria using Computerized Tomography (CT) assessment of tumor(s)
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Achieving Overall Survival at 6 Months
Time Frame: 6 Months
|
Overall survival assessed at 6 months since diagnosis of progression on first-line therapy
|
6 Months
|
Number of Participants With Responses as Determined by RECIST Criteria Using CT or Magnetic Resonance Imaging (MRI) Assessment
Time Frame: 2 years
|
Tumor response rate as determined by RECIST criteria using CT or Magnetic Resonance Imaging (MRI) assessment of tumor size every 3 months
|
2 years
|
Adverse Events
Time Frame: 1 years
|
Number of adverse events by grade
|
1 years
|
60 Day All-cause Mortality Rate
Time Frame: 60 days
|
Number of Participants with 60 Day All-cause Mortality
|
60 days
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Liver Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Neoplasms
- Colorectal Neoplasms
- Adenocarcinoma
- Liver Neoplasms
Other Study ID Numbers
- 071960
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Neoplasms
-
Ethicon, Inc.RecruitingLiver Cancer | Cancer of the Liver | Neoplasms, LiverUnited Kingdom, United States, Netherlands, Singapore, France, Germany, China, Korea, Republic of
-
Ethicon, Inc.Terminated
-
Ewha Womans University Mokdong HospitalSeoul St. Mary's Hospital; Pusan National University Hospital; Chonnam National... and other collaboratorsUnknown
-
China Medical University HospitalActive, not recruitingLiver Transplant, Liver Cancer, ImmunosuppressantTaiwan
-
Fuda Cancer Hospital, GuangzhouShenzhen Hank Bioengineering InstituteCompletedLiver Tumor | Evidence of Liver TransplantationChina
-
Slawa CwajnaNova Scotia Health AuthorityWithdrawnPrimary Liver Cancer | Metastatic Liver CancerCanada
-
Tel-Aviv Sourasky Medical CenterCompletedPrimary Liver Tumor, Metastatic LiverIsrael
-
Chinese Academy of SciencesRecruiting
-
Dana-Farber Cancer InstituteBrigham and Women's HospitalCompleted
-
Assistance Publique - Hôpitaux de ParisFLUOPTICSUnknown
Clinical Trials on Yttrium-90 Radioactive Resin Microspheres
-
Seoul National University HospitalRecruitingHepatocellular CarcinomaKorea, Republic of
-
H. Lee Moffitt Cancer Center and Research InstituteBTG International Inc.CompletedCholangiocarcinomaUnited States
-
M.D. Anderson Cancer CenterSirtex MedicalRecruiting
-
Sirtex MedicalBright Research PartnersRecruitingUnresectable Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | BCLC Stage A Hepatocellular CarcinomaUnited States
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)CompletedLocalized Non-Resectable Adult Liver CarcinomaUnited States
-
GrandPharma (China) Co., Ltd.Not yet recruiting
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)TerminatedLiver CancerUnited States
-
Zhongda HospitalRecruitingUnresectable Hepatocellular CarcinomaChina
-
Chengdu New Radiomedicine Technology Co. LTD.RecruitingUnresectable Hepatocellular CarcinomaChina
-
Methodist Health SystemRecruitingHepatocellular CarcinomaUnited States